InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the complete record of transactions filed by Evans John M., Chairman & CEO. Director active across 1 companies, notably Beam Therapeutics Inc.. Cumulatively, 12 filings have been published. Total volume traded: €66k. The latest transaction was filed on 28 April 2022 — Levée d'options. Regulator: SEC (Form 4). All data is free.
Declarations12 total
€84,17212,246 shares@ €6.87340.0029% mcap34.6% of flow
Common Stock
SEC:0000899243-22-016164:0·
056,250 shares0
Common Stock
SEC:0000899243-22-013487:0·
012,000 shares0
Common Stock
SEC:0000899243-22-004197·
012,000 shares0
Common Stock
SEC:0000899243-22-004197:0·
€24,69127,700 shares@ €0.89140.0009% mcap31.0% of flow
Common Stock
SEC:0000899243-21-039697·
€24,69127,700 shares@ €0.89140.0009% mcap10.2% of flow
Common Stock
SEC:0000899243-21-039697:0·
€33,016400 shares@ €82.54120.0011% mcap41.5% of flow
Common Stock
SEC:0000899243-21-033848·
€33,016400 shares@ €82.54120.0011% mcap13.6% of flow
Common Stock
SEC:0000899243-21-033848:0·
€21,83425,000 shares@ €0.87340.0008% mcap27.5% of flow
Common Stock
SEC:0000899243-21-027903·
€21,83425,000 shares@ €0.87340.0008% mcap9.0% of flow
Common Stock
SEC:0000899243-21-027903:0·
032 shares0
Common Stock
SEC:0000899243-21-026781·
032 shares0
Common Stock
SEC:0000899243-21-026781:0·
12 of 12 declarations
About Evans John M.
John M. Evans is the Chief Executive Officer of Beam Therapeutics Inc. He is responsible for the strategic direction of the company, which focuses on developing innovative gene therapies. Under his leadership, Beam Therapeutics is committed to transforming healthcare through gene-editing-based solutions. John brings deep expertise in biotechnology and management, contributing to advancing the company's mission to improve patients' lives.
